bupropion studies
Select the study ID number to view the trial summary
| Study ID | Phase | Title |
| AK110016 | IV | Final study report for a randomized, single-dose, three-way crossover study examining the bioequivalence of a reformulated WELLBUTRIN SR 100 mg tablet formulation versus the currently-marketed WELLBUTRIN SR 100 mg tablet formulation in healthy volunteers. |
| AK1A1003 | IV | An open-label, 30 day study to investigate the potential pharmacokinetic interaction of multiple doses (300mg/day) of WELLBUTRIN SR (bupropion hydrochloride) on single doses (50mg) of desipramine in normal volunteers designated extensive metabolizers via the CYP2D6 pathway. |
| AK1A4008 | IV | A Multi-Centre, Parallel, Randomised, Open-label, 1-Year Evaluation of the Effects of Zyban [bupropion hydrochloride sustained release tablets – BUP(SR)] and Nicorette DS (nicotine polacrilex double strength) as Aids to Smoking Cessation in Adult Chronic Cigarette Smokers |
| AK1A4010 | IV | A Parallel, Randomized, Double-Blind, Placebo-Controlled, 1-Year Pilot Study of the Effects of ZYBAN† (Bupropion Hydrochloride Sustained Release Tablets) as an Aid to Smoking Cessation in Adult Cigarette Smokers Who are Not Motivated to Quit Smoking |
| AK1A4013: Follow-up phase | IV | A multicenter evaluation of the effects of Zyban™ (bupropion hydrochloride sustained release tablets) versus placebo in a population of smokers with COPD: Follow-up phase. ZYBAN is a registered trademark of the GlaxoSmithKline group of companies. |
| AK1A4013: Treatment phase | IV | A multicenter evaluation of the effects of Zyban™ (bupropion hydrochloride sustained release tablets) versus placebo in a population of smokers with COPD: treatment phase. |
| Bupropion Suicidality Re-Analyses | IV | Re-analysis of data in bupropion clinical trials for suicidality |
| India – Zyban | IV | Post Marketing Surveillance of Zyban-SR (Bupropion hydrochloride) in the Treatment of Nicotine Dependence Among Indian Patients |
| WE105 (EPI40140) | IV | Bupropion – Final Prescription Event Monitoring Report on 11,735 Patients |
| Well 86A | IV | Prospective open evaluation of the seizure incidence with bupropion hydrochloride (Wellbutrin®) |
| WELL AK130931 | IV | A multicenter, double-blind, placebo-controlled comparison of the efficacy and safety of flexible dose extended-release bupropion hydrochloride (HCl) 300-450mg/day and placebo administered for eight weeks for the treatment of adult outpatients with major depressive disorder including symptoms of decreased energy, pleasure, and interest. |
| WELL AK130934 | IV | An 8-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Comparison of Extended-Release Bupropion Hydrochloride 300-450 mg/day to Assess the Efficacy, Safety, and Effects on Health Outcomes in the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder |
| WELL AK140016 | IV | An eight-week double-blind study comparing the effects of 20 mg of paroxetine to 150 mg of Wellbutrin SR in patients with Major Depressive Disorder |
| WELL AK1A4001 | IV | A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Effects on Sexual Functioning of Wellbutrin (Bupropion HCI) Sustained Release and Sertraline in Outpatients with Moderate to Severe Recurrent Major Depression |
| WELL AK1A4002 | IV | A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Effects on Sexual Functioning of Wellbutrin (Bupropion HCl) Sustained Release and Sertraline in Outpatients with Moderate to Severe Recurrent Major Depression |
| WELL AK1A4003 | IV | A Multicenter, Double-Blind, Randomized Pilot Study Comparing the Safety and Efficacy of Wellbutrin (Bupropion HCl) Sustained Release and Paroxetine in the Treatment of Elderly Outpatients with Moderate to Severe Recurrent Major Depression |
| WELL AK1A4004 | IV | A Multicenter Placebo-Controlled Study of WELLBUTRIN (Bupropion Hydrochloride) Sustained Release (SR) for the Prevention of Relapse/Recurrence in Subjects Whose Depression Responded to Treatment With WELLBUTRIN SR |
| WELL AK1A4006 | IV | A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Safety and Efficacy and Effects on Sexual Functioning of Wellbutrin (Bupropion HCl) Sustained Release (SR) and Fluoxetine in Outpatients with Moderate to Severe Recurrent Major Depression |
| WELL AK1A4007 | IV | A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Safety and Efficacy and Effects on Sexual Functioning of Wellbutrin (Bupropion HCl) Sustained Release (SR) and Fluoxetine in Outpatients with Moderate to Severe Recurrent Major Depression |
| WELL ZYB40021 | IV | A 6 Month Multicenter, Randomized, Double-Blind, Pilot Study to Investigate the Tolerability and Efficacy of Bupropion SR Compared to Placebo for the Treatment of Mild Depressive Symptoms and Obesity, Followed by a 24-week Open-Label Extension |
| ZYB AK1A4011 | IV | An open-label study to evaluate Zyban as an aid to smoking cessation treatment in adult smokers receiving Medicaid. |
| ZYB30009 | IV | A multi-centre, randomised, double-blind, placebo controlled, 6 month study to evaluate the efficacy and tolerability of bupropion hydrochloride sustained release tablets for the treatment of nicotine dependence as an aid to smoking cessation in a healthcare professionals and hospital staff population at hospitals in Denmark. |
| ZYB40001 | IV | A randomized, double-blind, placebo-controlled, 12-week smoking cessation trial of Zyban (150 mg bid) in adult smokers previously treated with Zyban |
| ZYB40003 | IV | A multicenter, randomized, parallel, placebo-controlled, one-year study of the efficacy and safety of bupropion hydrochloride sustained-release tablets versus placebo as an aid to smoking cessation treatment in adult cigarette smokers previously treated with bupropion |
| ZYB40005 | IV | The effect of sustained-release bupropion HCl vs. placebo as an aid to smoking reduction leading to cessation among smokers unwilling and unable to quit smoking |
| ZYB40011 | IV | A multi-centre, randomised, double-blind, placebo-controlled, one-year study to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) (sustained release tablets) for the treatment of nicotine dependence as an aid to smoking cessation in population of healthcare professionals. |
| ZYB40014 | IV | A multi-center, randomised, parallel-group, double-blind, placebo-controlled one year study (with a 7 week Treatment Phase) to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) versus placebo as an aid to smoking cessation in a population of smokers with established, stable cardiovascular disease |
| ZYB40017 | IV | A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, One-Year Study to Evaluate the Efficacy and Safety of Bupropion Hydrochloride (SR) (Sustained-Release Tablets) for the Treatment of Nicotine Dependence as an Aid to Smoking Cessation. |
| ZYB40030 | IV | A Multi-centre, Randomised, Double-Blind, Placebo controlled study to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) sustained release versus placebo as an aid to smoking cessation in a population of smokers with Chronic Obstructive Pulmonary Disease. |
| ZYB40033 | IV | A multi-centre, open, one-year study to evaluate the efficacy and safety of bupropion hydrochloride (sustained release tablets) for the treatment of nicotine dependence as an aid to smoking cessation in a population of smokers either without any medical condition, with chronic obstructive pulmonary disease or with established, stable cardiovascular disease. |
| ZYB40036 | IV | A single-country, multi-centre, open-label study to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) (sustained release tablets) for the treatment of nicotine dependence as an aid to smoking cessation in patients with chronic bronchitis. |
| ZYB40041 | IV | An open-label, multicentre study with general practitioners to assess efficacy and safety of Bupropion SR (2x150mg per day) as an aid to smoking cessation in patients who were previously treated with Bupropion SR or NRT |
| ZYB40045 | IV | An open one year study to evaluate the efficacy and safety of bupropion hydrochloride (QuomenÔ) for smoking cessation in smokers with mild to moderate chronic obstructive pulmonary disease (COPD) |
| ZYBF 4001 | IV | Evaluation of efficacy of safety of ZybanTM (bupropion hydrochloride extended release tablet) in smoking cessation aid in nicotine-dependent patients. Multicentre, randomized, double blind, placebo-controlled study, 6 months length. |
| ZYBPL01 | IV | Efficacy and safety of Bupropion ( Zyban, GlaxoSmithKline ) for the treatment of smoking cessation in patients with chronic bronchitis. |
| 13 | III | Ninety-eight day, parallel, double-blind, randomized comparison of placebo, bupropion and amitriptyline (75-200mg/day) in outpatients, ages 55 and older |
| 15 | III | Thirteen week, parallel, double blind, randomized comparison of bupropion versus amitriptyline (75-100mg/day) in outpatients |
| 16 | III | Double-Blind Comparison of Doxepin versus Bupropion in Outpatients with a Major Depressive Disorder |
| 21 | III | Six week, parallel, double blind, randomized comparison of bupropion versus amitriptyline (75-225mg/day) in inpatients |
| 48 | III | Cardiovascular effects of Bupropion in Depressed Patients with Heart Disease. |
| 49 | III | Cardiovascular effects of Bupropion in Depressed Patients with Heart Disease. |
| 54 | III | Disposition of Bupropion in Healthy volunteers and subjects with alcoholic liver disease. |
| 58 | III | A Double-Blind, Placebo-Controlled Trial of Bupropion SR for SSRI-Induced Sexual Dysfunction |
| 75 | III | Six-week, multicenter, double-blind, randomized, parallel comparison of the efficacy and safety of bupropion versus placebo in children with attention deficit disorder |
| 83 | III | Treatment of Bulimia with Bupropion: A Multicenter Controlled Trial |
| 88 | III | Double-Blind Comparison of Bupropion and Fluoxetine in Depressed Outpatients |
| 89 | III | Six-week, parallel, double-blind, randomized comparison of bupropion and trazodone (150-400mg/day) in outpatients |
| 90 | III | The Cardiovascular Effects of Bupropion and Nortriptyline in Depressed Outpatients |
| 300 | III | A Multicenter Trial of Bupropion for Cocaine Dependence in Methadone-Maintained Patients |
| 404 | III | Effect of chronic Wellbutrin SR administration on craving, withdrawal, and impairment of cognitive performance associated with nicotine abstinence. |
| AK1102369 | III | Clinical Evaluation of bupropion sustained release in patients with Depression -Investigation in Elderly patients with Depression |
| AK1105695 | III | A Post-Marketing Surveillance (PMS) to monitor the safety of Wellbutrin SRTM (bupropion sustained-release) administered in Korean subjects according to the prescribing information |
| AK130939 | III | A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150mg - 300mg once daily), Extended-Release Venlafaxine Hydrochloride (75mg - 150mg once daily) and Placebo in Subjects with Major Depressive Disorder. |
| AK130940 | III | A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of Extended-release Bupropion Hydrochloride (150mg-300mg once daily) in Elderly Subjects with Major Depressive Disorder. |
| AK1A403 | III | A multicenter dose response evaluation of Wellbutrin† (Bupropion hydrochloride) sustained release versus placebo as an aid to smoking cessation. |
| WELL 100006 | III | A 7-Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison of 150-300mg/day of Extended-Release Bupropion Hydrochloride (WELLBUTRIN XL) and Placebo for the Prevention of Seasonal Affective Disorder in Subjects with a History of Seasonal Affective Disorder Followed by an 8-Week Observational Follow-up Study. |
| WELL 208 | III | Safety Surveillance Study for WELLBUTRIN® (bupropion hydrochloride) Sustained Release |
| Well 209 | III | The Safety and Efficacy of Wellbutrin Sustained Release and Sertraline in Depressed Outpatients |
| Well 84A | III | Multicenter evaluation of the efficacy and safety of a 300 mg daily dose of Wellbutrin versus placebo in depressed outpatients |
| WELL AK130926 | III | A Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Effects on Sexual Functioning of Extended-Release Bupropion Hydrochloride (300-450 mg) and Escitalopram (10-20 mg) in Outpatients with Moderate to Severe Major Depression over an Eight-Week Treatment Period |
| WELL AK130927 | III | A Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Effects on Sexual Functioning of Extended-Release Bupropion Hydrochloride (300-450 mg) and Escitalopram (10-20 mg) in Outpatients with Moderate to Severe Major Depression over an Eight-Week Treatment Period |
| WELL AK130930 | III | A 7-Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison of 150-300mg/day of Extended-Release Bupropion Hydrochloride (WELLBUTRIN XL) and Placebo for the Prevention of Seasonal Affective Disorder in Subjects with a History of Seasonal Affective Disorder Followed by an 8-Week Observational Follow-up Phase. |
| WELL AK130936 | III | A 7-Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison of 150-300mg/day of Extended-Release Bupropion Hydrochloride (WELLBUTRIN XL) and Placebo for the Prevention of Seasonal Affective Disorder in Subjects with a History of Seasonal Affective Disorder Followed by an 8-Week Observational Follow-up Phase. |
| Wellbutrin 25 | III | Multicenter Evaluation of the Efficacy and Safety of Bupropion vs. Placebo in Depressed Inpatients |
| WXL101497 | III | A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150mg - 300mg once daily), Extended-Release Venlafaxine Hydrochloride (75mg - 150mg once daily) and Placebo in Subjects with Major Depressive Disorder |
| ZYB 30011 | III | A multicentre, randomised, double- blind, placebo controlled study to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) sustained release (2 x 150mg per day) versus placebo as an aid to smoking cessation in smokers with at least one cardiovascular (CV) risk factor. |
| ZYB AK1A405 | III | A Multicenter Evaluation of Wellbutrin (Bupropion Hydrochloride) Sustained Release, Habitrol (Nicotine Transdermal System), and Combination Wellbutrin Sustained Release/Habitrol Treatment Versus Placebo as Aids to Smoking Cessation. |
| ZYB AK1A406 | III | A multicenter comparison of bupropion hydrochloride sustained-release versus placebo for the prevention of relapse in patients who quit smoking while taking bupropion sustained-release |
| ZYB30005 | III | An open-label, multicentre study with general practitioners to assess efficacy and safety of Bupropion SR (2x150mg) dependent on (sub)-depression and motivation |
| 9 | II | Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients |
| 14 | II | Phase II Multicenter Evaluation of the Efficacy and Safety of Bupropion vs. Placebo in Depressed Inpatients |
| AK1 102364 | II | Clinical evaluation of bupropion sustained release in subjects with depression - Open-label study - |
| AKIA401 | II | A single-center evaluation of Wellbutrin (bupropion hydrochloride) versus placebo as an aid to smoking cessation in heavy smokers (study 401) |
| SMK20001 | II | A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group, Dose Response Evaluation of a New Chemical Entity (NCE) and ZYBAN (bupropion hydrochloride) Sustained Release (300mg/day) versus Placebo As Aids to Smoking Cessation. |
| WELL 029 | II | Multicenter Evaluation of the Efficacy and Safety of Low Doses of Wellbatrin vs. Placebo in Depressed Inpatients |
| Well 08 | II | Phase II Placebo-Controlled Evaluation of Efficacy: Multiclinic Study |
| WELL 203 | II | A Multicenter Evaluation of the Safety and Efficacy of 150mg/day and 300mg/day of Bupropion HCl Sustained-Release Versus Placebo in Depressed Outpatients |
| WELL 205 | II | A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients |
| WELL 212 | II | A multicenter evaluation of the safety and efficacy of two flexible doses of WELLBUTRIN sustained-release versus placebo in depressed outpatients |
| Well 41 | II | A Single-Blind Pilot Study of the Safety and Efficacy of Wellbutrin in Children with Attention Deficit and/or Conduct Disorders |
| WELL100368 | II | A Twelve-week, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group, Active-controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of Bupropion Hydrochloride Extended-release (WELLBUTRIN® XL, 150-450 mg/day) and Extended-release Venlafaxine (Effexor XR, 75-225 mg/day) in Subjects with Major Depressive Disorder |
| Wellbutrin 06 | II | Phase II Placebo-Controlled Proof of Efficacy, Multi-clinic Study |
| WXL101969 | II | A Study to Evaluate the Effect of Repeated Oral Doses of WELLBUTRIN XL® Compared with Placebo and Single Oral Doses of Moxifloxacin on Cardiac Conduction as assessed by 12-lead Electrocardiogram |
| ZYB AKIA402 | II | A single center evaluation of Wellbutrin (bupropion hydrochloride) versus placebo as an aid to smoking cessation (study 402) |
| 82 | I | The disposition of bupropion and its metabolites in healthy male volunteers after administration of single and multiple doses of bupropion. |
| 96 | I | Steady-State Pharmacokinetics of Two Daily Oral Doses of Wellbutrin and Its Basic Metabolites in Normal Volunteers |
| 201 | I | Single-Dose Bioequivalence of WELLBUTRIN® Sustained-Release Tablets Versus WELLBUTRIN Immediate-Release Tablets in Healthy Male Volunteers: A Pilot Study |
| 202 | I | A Single-Dose Bioequivalence/Effect of Food Evaluation of WELLBUTRIN® Sustained-Release |
| 204 | I | A single-dose bioavailability evaluation of the 50 and 100mg WELLBUTRINÒ sustained-release tablets in healthy male volunteers |
| 206 | I | Steady-state bioequivalence evaluation of bupropion sustained-release and bupropion immediate-release tablets in healthy male volunteers |
| 207 | I | A bioequivalence study of 50, 100, and 150 mg bupropion sustained-release tablets in healthy male volunteers |
| 407 | I | Pharmacokinetics and metabolism of Wellbutrin (bupropion hydrochloride) sustained-release in healthy smokers versus non-smokers. |
| 01A | I | Bupropion – A double-blind toxicity study. |
| 11UK | I | Comparison of the effects of bupropion, dextroamphetamine and amitriptyline on human performance tests, autonomic responses, EEG and subjective rating scales. |
| 40UK | I | Effect of multiple doses of bupropion on antipyrine disposition in healthy volunteers. |
| 40UKA | I | The disposition of bupropion and its basic metabolites in young and elderly healthy volunteers. |
| AK110022 | I | An open-label, randomized, single-dose, two-way crossover study examining the bioequivalence of one newly formulated WELLBUTRIN SR† 200mg tablet versus two currently marketed WELLBUTRIN SR 100mg tablets in healthy volunteers. |
| AK1A1001 | I | A randomized, crossover study to evaluate the pharmacokinetic effect of cimetidine on WELLBUTRIN (Bupropion HCl) sustained release in healthy subjects. |
| AK1B1001 | I | The pharmacokinetics and tolerability of Wellbutrin SR after oral administration of a single 150 mg dose in patients with liver cirrhosis and healthy volunteers |
| AK1BIOVAIL2526 | I | A pilot, one-period, three-way, cross-over, steady state, open-label, multiple-dose, fasting, comparative bioavailability study of two formulations of bupropion hydrochloride (HCl) extended release tablets (1 ´ 300mg q.d.) versus WELLBUTRIN™ tablets (1 ´ 100mg b.i.d. and t.i.d.) in normal healthy non-smoking male volunteers. |
| AK1BIOVAIL2543 | I | A two-way, crossover, steady state, multiple-dose, open-label, fasting, comparative bioavailability study of bupropion HCI 300mg extended release tablets (1 X 300mg q.d.) versus WELLBUTRIN 100mg tablets (t.i.d.) in normal healthy non-smoking male and female subjects |
| AK1BIOVAIL2544 | I | A two-way, crossover, steady state, multiple-dose, open-label, fasting, comparative bioavailability study of bupropion HCl 300 mg extended release tablets (1 ´ 300 mg q.d.) versus Wellbutrin 100 mg tablets (t.i.d.) in normal healthy non- smoking male and female subjects |
| AK1BIOVAIL2548 | I | A two-way, crossover, open-label, single dose, food-effect, comparative bioavailability study of bupropion HCI extended release 300mg tablets in normal healthy non-smoking male and female subjects |
| AK1BIOVAIL2571 | I | A two-way, crossover, open-label, single-dose, fasting, dosage strength equivalency study of two strengths (150mg and 300mg) of bupropion HCI extended release tablets given once daily in normal healthy non-smoking male and female subjects |
| AK1BIOVAIL2572 | I | A two-way, steady state, crossover, open-label, multiple-dose, fasting, comparative bioavailability study of bupropion HCI 300 mg extended-release tablets versus ZYBAN† 150 mg tablets in normal healthy non-smoking male and female subjects. |
| AK1BIOVAIL2573 | I | A four-way, crossover, open-label, single-dose, fasting and food effect, comparative bioavailability study of bupropion HCl extended-release 150mg tablets and Zybanâ 150mg tablets in normal healthy non-smoking male and female subjects |
| AK1BIOVAIL2594 | I | A four-period, four-treatment, crossover, open-label, single-dose, fasting, in-vitro/in-vivo correlation pharmacokinetic study of three formulations of bupropion HCl extended release 150 mg tablets (fast release, target release and slow release formulations) and bupropion HCl 100 mg oral solution in normal healthy non-smoking male subjects |
| B04-689PK-P05P2 | I | A two-way, steady-state, fasting, dosage form proportionality study of 150 mg Wellbutrin XL™ tablets and 450 mg bupropion extended-release tablets in normal healthy non-smoking male and female subjects. |
| B04-696PK-P05P2 | I | A two-way, steady-state, fasting, dosage form proportionality study of 150 mg Wellbutrin XL™ tablets and 450 mg bupropion extended-release tablets in normal healthy non-smoking male and female subjects |
| OHB10001 | I | An open label positron emission tomography study to evaluate dopamine transporter occupancy, as measured by 11C-bCIT-FE following 150mg WELLBUTRIN SR twice daily for 8 days, in healthy male volunteers. |
| P02-027 | I | A Single Dose Metabolism Study of 14C-WellbutrinÔ in Normal Volunteers |
| P02-24 | I | Phase I - A comparison of bupropion, dextroamphetamine and placebo for abuse liability in amphetamine abusers |
| P02-31UK | I | Examination of Bupropion and Ethanol, Alone and in Combination, on Human Performance Tests, Subjective Rating Scales, EEG and Autonomic Responses |
| P02-36UK | I | Investigation of the Effects of Bupropion and Imipramine on the Blood Pressure Response to Tyramine in Man |
| P02-37UK | I | Comparison of the Effects of Bupropion, Nomifensine, and Dextroamphetamine on Performance Tests, Subjective Scales, Autonomic Responses, and Electroencephalograms in Healthy Human Volunteers |
| RES10983 | I | Double blind, randomised, placebo controlled, three periods, crossover study to investigate in a 72 hours enforced smoking cessation severity of withdrawal symptoms and craving in healthy volunteers on Zyban. |
| THRS/79/0010 (Well 18) | I | Examination of bupropion and diazepam, alone and in combination on human performance tests, subjective rating scales, EEG and autonomic responses |
| THRS/81/0012 (Well 07B) | I | Pharmacokinetics in normal volunteers |
| THRS/81/0023 (Well 20UK) | I | Effects of low doses of bupropion on plasma prolactin and growth hormone in normal subjects. |
| US01B | I | Wellbatrin: Preliminary pharmacokinetics |
| WELL AK110021 | I | Single-Center, Randomized, Double-Blind, Placebo-Controlled, Four-Week Study to Assess the Safety of Multiple Fixed Doses of WELLBUTRIN SR (bupropion hydrochloride sustained release) Tablets in Outpatients with Untreated Stage I Hypertension |
| WXL103104 | I | A randomized, crossover, 3-period, 2-way interaction study to evaluate potential drug interactions between WELLBUTRIN XL® and citalopram in healthy volunteers |
| WXL103106 | I | An open-label, 2-period, sequential treatment, 1-way drug interaction study to evaluate the effect of ritonavir on bupropion pharmacokinetics in healthy volunteers |
| WXL108709 | I | A cross-over study to evaluate the effect of WELLBUTRIN XL on intraocular pressure in healthy volunteers. |
| WXL108712 | I | An open-label, 2-period, sequential treatment, drug interaction study to evaluate the effect of low-dose ritonavir on buproprion pharmacokinetics in healthy volunteers |